Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

PHASE3CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

February 16, 2017

Conditions
Acromegaly
Interventions
DRUG

Lanreotide Autogel®

Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).

DRUG

Lanreotide Acetate

Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).

Trial Locations (10)

100730

Peking Union Medical College Hospital, Beijing

200040

Huashan Hospital Fudan University, Shanghai

210029

Jiangsu Provincial People's Hospital, Nanjing

300052

Tianjin Medical University General Hospital, Tianjin

350004

Fujian Provincial Hospital, Fuzhou

430030

Tongji Medical College Huazhong University of Science & Technology, Wuhan

510080

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

550004

Affiliate Hospital of Guiyang Medical College, Guizhou

610041

West China Hospital, Sichuan University, Chengdu

050000

The Second Hospital of Hebei Medical University, Shijiazhuang

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY